Fairvalue-Calculator Fairvalue-Calculator

LanZhou Foci Pharmaceutical Co (002644) Fair Value & Analysis

Healthcare · CN · Market cap 3.8B CNY

Price¥7.32
Fair Value¥3.96
Upside-45.9%
Quality94/100
Evidence: High Range ¥3.00 – ¥4.92

Analysis

LanZhou Foci Pharmaceutical Co (002644) currently trades at ¥7.32, while our model-based Fair Value estimate is ¥3.96 — implying the stock looks roughly 45.9% overvalued today. We read business quality at 94/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

LanZhou Foci Pharmaceutical Co.,Ltd., research and development, production, and sales of traditional Chinese medicines and health products in China. The company offers its products in various dosage forms, including pills, tablets, granules, capsules, and gelatin under the MingShan, BaoShu, BaoLu, and Foci brands. It also engages in planting and selling of Chinese medicinal materials; pre-packaged food; processing and selling of Chinese herbal medicine pieces; technology development, and professional and technical services; inspection and testing services; and production and sales of medical devices. The company exports its products. LanZhou Foci Pharmaceutical Co.,Ltd. was founded in 1929 and is based in Lanzhou, China. LanZhou Foci Pharmaceutical Co.,Ltd. operates as a subsidiary of Lanzhou Foci pharmaceutical industry development Group co., ltd.

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +885% Jiangsu Hengrui Pharmaceuticals Co (600276) -44% Sun Pharmaceutical Industries Limited (SUNPHARMA) -49% Zoetis Inc (Z1TS34) -75% Hansoh Pharmaceutical Group (3692) -18% Divi's Laboratories Limited (DIVISLAB) -78%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.